Champions Oncology, Inc.: Form 10-Q for the period ended Jan 31, 2025
Filed with the SEC on Mar 17, 2025 and accepted by EDGAR at Mar 17, 2025, 15:03 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2025-01-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2024-11-01 to 2025-01-31 | $17.0m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Revenue | 9 months2024-05-01 to 2025-01-31 | $44.6m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Cost of revenue | 3 months2024-11-01 to 2025-01-31 | $6.6m | us-gaap:CostOfGoodsAndServicesSold |
| Cost of revenue | 9 months2024-05-01 to 2025-01-31 | $21.1m | us-gaap:CostOfGoodsAndServicesSold |
| Research and development | 3 months2024-11-01 to 2025-01-31 | $1.7m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 9 months2024-05-01 to 2025-01-31 | $4.9m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months2024-11-01 to 2025-01-31 | $4.5m | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months2024-05-01 to 2025-01-31 | $6.6m | us-gaap:OperatingIncomeLoss |
| Income tax | 3 months2024-11-01 to 2025-01-31 | $23.0k | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 9 months2024-05-01 to 2025-01-31 | $54.0k | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2024-11-01 to 2025-01-31 | $4.5m | us-gaap:NetIncomeLoss |
| Net income | 9 months2024-05-01 to 2025-01-31 | $6.5m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2024-11-01 to 2025-01-31 | $0.31 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 9 months2024-05-01 to 2025-01-31 | $0.46 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2024-11-01 to 2025-01-31 | $0.33 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 9 months2024-05-01 to 2025-01-31 | $0.48 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2024-11-01 to 2025-01-31 | 14,364,904 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 9 months2024-05-01 to 2025-01-31 | 14,132,712 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 9 months2024-05-01 to 2025-01-31 | $518.0k | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 9 months2024-05-01 to 2025-01-31 | $136.0k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Share repurchases | 9 months2024-05-01 to 2025-01-31 | $0 | us-gaap:PaymentsForRepurchaseOfCommonStock |
| Cash and equivalents | At period end2025-01-31 | $3.2m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2025-01-31 | $19.7m | us-gaap:AssetsCurrent |
| Total assets | At period end2025-01-31 | $30.6m | us-gaap:Assets |
| Current liabilities | At period end2025-01-31 | $19.9m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2025-01-31 | $25.2m | us-gaap:Liabilities |
| Shareholders' equity | At period end2025-01-31 | $5.5m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001628280-25-012941. Last ingested by Listed: Oct 24, 2026, 14:56 ET. Listed shows no prices and gives no investment advice.